国内外HER-2/neu基因扩增型胃癌临床病理及预后特征分析  

Analysis of clinicopathological and prognostic characteristics of HER-2/neu gene amplification gastric cancer at home and abroad

作　　者：黄秀芳[1] 原向伟[2] 刘琼茹[1] 梁津杰 方晓华[1] 蔡育波 杨文丽[1] 黄辉 陈艳虹 陈仙兰 张鑫[1,3] 林碧华 HANG Xiufang;YUAN Xiangwei;LIU Qiongru;LIANG Jinjie;FANG Xiaohua;CAI Yubo;YANG Wenli;HUANG Hui;CHEN Yanhong;CHEN Xianlan;ZHANG Xin;LIN Bihua(Department of Pathology,Jiangmen Central Hospital,Jianmen 529030,China;Department of Orthopaedics,Jiangmen Central Hospital,Jianmen 529030,China;Guangdong Key Laboratory of Medical Molecular Diagnostics,Guangdong Medical University,Dongguan 523808,China;Department of Biochemistry and Molecular Biology,Guangdong Medical University,Dongguan 523808,China)

机构地区：[1]广东省江门市中心医院病理科,广东江门529030 [2]广东省江门市中心医院脊柱骨科,广东江门529030 [3]广东医科大学广东省医学分子诊断重点实验室,广东东莞523808 [4]广东医科大学生物化学与分子生物学教研室,广东东莞523808

出　　处：《中国医药科学》2018年第19期9-12,35,共5页China Medicine And Pharmacy

基　　金：国家自然科学基金项目(81272434);广东省科技创新战略专项资金(基础与应用基础研究等方向)立项项目(2018A030310007);广东省医学科研基金项目(A2016395;A2017103);广东省中医药局科研项目(20172085;20181273);广东省东莞市医疗卫生科技计划项目(2016105101292);广东省江门市科技计划项目[江科(2013)81-30]

摘　　要：目的比较国内外胃癌患者中人表皮生长因子2基因(HER-2/neu)扩增与临床病理及预后的关系。方法从肿瘤基因组图谱数据库(TCGA)中,获国外441例胃癌的全基因组拷贝数变异数据和与临床病理及预后数据,利用GISTIC2.0软件分析TCGA患者肿瘤组织中HER-2/neu基因拷贝数变异情况。收集2008～2014年江门市中心医院404例胃癌患者信息,利用荧光原位杂交技术检测癌组织中HER-2/neu的扩增。分析两组数据HER-2/neu扩增与临床病理及预后的相关性。结果 HER-2/neu基因在TCGA及江门市中心医院胃癌患者中的扩增率分别为14.7%(65/441)和17.1%(69/404),无显著性差异。男性HER-2/neu扩增率高于女性,低、中病理分级的HER-2/neu扩增率高于高病理分级,而与年龄、T、N、M分期及临床分期无关。两组HER-2/neu扩增患者的中位生存时间是26.4个月和38.8个月,HER-2/neu非扩增患者的中位生存时间是29.4个月和39.1个月,两群患者的生存预后差异无统计学意义。结论在国内外的胃癌患者中,HER-2/neu扩增与男性及高分化程度相关。Objective To compare the relationship between human epidermal growth factor 2 gene （HER-2/ neu） amplification and clinicopathology and prognosis in gastric cancer patients at home and abroad. Methods The genome-wide copy number variation data and clinicopathological and prognostic data of 441 Cases of gastric cancer were obtained from the Tumor Genome Mapping Database （TCGA）. The HER-2/neu gene copy number variation in TCGA patients was analyzed by using GIS TIC2.0 software. The information of 404 patients with gastric cancer in Jiangmen Central Hospital from 2008 to 2014 was collected. The HER-2/neu amplification in cancer tissues was detected by fluorescence in situ hybridization （FISH）. The correlation between HER-2/neu amplification and clinical pathology and prognosis of the two groups was analyzed. Results The amplification rates of I-IER-2/ neu gene in gastric cancer patients at TCGA and Jiangmen Central Hospital were 14.7% （65/441） and 17.1% （69/404）, respectively, with no significant difference. The HER-2/neu amplification rate of males was higher than that of females. The HER-2/neu expansion rate of low and medium pathological grades was higher than that of high pathological grades, but not with age, T, N, M stage and clinical stage. The median survival time of the two groups of HER-2/neu-expanded patients was 26.4 months and 38.8 months, and the median survival time of HER-2/neu non- amplified patients was 29.4 months and 39.1 months. There was no significant difference in survival prognosis. Conclusion HE1R-2/neu amplification is associated with male and high degree of differentiation in gastric cancer patients at home and abroad.

关 键 词：胃癌 人表皮生长因子2基因 基因拷贝数变异 荧光原位杂交 临床病理 

分 类 号：R735.2[医药卫生—肿瘤]